Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations

BLOOD

AMER SOC HEMATOLOGY

1. Else Kroner-Fresenius-Stiftung grant [2010_Kolleg24, 01KT1601]
2. FIRE CLL
3. Deutsche Forschungsgemeinschaft [SFB 1074]
4. GILEAD (B.M.B.F.)
5. GILEAD
6. Swedish Research Council
7. Knut and Alice Wallenberg Foundation
8. Swedish Cancer Society
9. Karolinska Institutet
10. Karolinska University Hospital
11. Radiumhemmets Forskningsfonder, Stockholm
12. Associazione Italiana per la Ricerca sul Cancro-AIRC, Milan, Italy [20246]
13. [031L0076C PRECISe]